Increased risk for EBV-lymphoma after allogeneic HSCT in adult lymphoma patients? A retrospective study of reduced compared to myeloablative conditioning.

被引：0
|
作者：
Hagglund, HG
Brune, M
Oberg, G
Hagberg, H
Theorin, N
Remberger, M
Kimby, E
机构：
[1] Karolinska Univ Hosp, Karolinska Inst, Stockholm, Sweden
[2] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden
[3] Univ Uppsala Hosp, Uppsala, Sweden
[4] Linkoping Univ Hosp, S-58185 Linkoping, Sweden
[5] Huddinge Univ Hosp, Karolinska Inst, Stockholm, Sweden
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5116
引用
收藏
页码：362B / 363B
页数：2
相关论文
共 50 条
  • [31] Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party
    Robinson, Stephen P.
    Boumendil, Ariane
    Finel, Herve
    Peggs, Karl S.
    Chevallier, Patrice
    Sierra, Jorge
    Finke, Juergen
    Poire, Xavier
    Maillard, Natacha
    Milpied, Noel
    Yakoub-Agha, Ibrahim
    Koh, Mickey
    Kroeger, Nicolaus
    Nagler, Arnon
    Koc, Yener
    Dietrich, Sascha
    Montoto, Silvia
    Dreger, Peter
    BONE MARROW TRANSPLANTATION, 2018, 53 (05) : 617 - 624
  • [32] Increased risk of second malignancies inchronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study
    Beiggi, S.
    Johnston, J. B.
    Seftel, M. D.
    Pitz, M. W.
    Kumar, R.
    Banerji, V.
    Griffith, E. J.
    Gibson, S. B.
    BRITISH JOURNAL OF CANCER, 2013, 109 (05) : 1287 - 1290
  • [33] Risk of Infectious Complications in Adult Patients After Allogeneic HSCT Depending on The Site of Central Venous Catheter Insertion - Multicentre Prospective Study
    Snarski, Emilian
    Stringer, Jacqui
    Mikulska, Malgorzata
    Gil, Lidia
    Tidello, Gloria
    Bosman, Paul
    Hoek, Jennifer
    Karas, Michal
    Zver, Samo
    Lueck, Catherina
    Blijlevens, Nicole
    Gonzalez, Iria
    Ociepa-Wasilkowska, Malgorzata
    Gorka, Michal
    Sanchez-Ortega, Isabel
    Andersson, Inger
    Yanez, Lucrecia
    Bekadja, Mohamed Amine
    Styczynski, Jan
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 453 - 454
  • [34] Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire
    Le Bourgeois, A.
    Labopin, M.
    Blaise, D.
    Ceballos, P.
    Vigouroux, S.
    de Latour, R. Peffault
    Marcais, A.
    Bulabois, C. E.
    Bay, J. O.
    Chantepie, S.
    Deconinck, E.
    Daguindau, E.
    Contentin, N.
    Yakoub-Agha, I.
    Cornillon, J.
    Mercier, M.
    Turlure, P.
    Charbonnier, A.
    Rorhlich, P. S.
    N'Guyen, S.
    Maillard, N.
    Marchand, T.
    Mohty, M.
    Chevallier, P.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2191 - 2198
  • [35] Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen
    Shigematsu, A.
    Yamamoto, S.
    Sugita, J.
    Kondo, T.
    Onozawa, M.
    Kahata, K.
    Endo, T.
    Shiratori, S.
    Ota, S.
    Yamaguchi, K.
    Wakasa, K.
    Takahata, M.
    Goto, H.
    Ito, S.
    Takemura, R.
    Tanaka, J.
    Hashino, S.
    Nishio, M.
    Koike, T.
    Asaka, M.
    Imamura, M.
    TRANSPLANT INFECTIOUS DISEASE, 2010, 12 (05) : 412 - 420
  • [36] Cure of adult T-cell leukemia/lymphoma by allogeneic stem cell transplantation with reduced conditioning intensity - End results for the patients who received prospective trials
    Choi, I.
    Utsunomiya, A.
    Tanosaki, R.
    Suehiro, Y.
    Kannagi, M.
    Okamura, J.
    Uike, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S658 - S658
  • [37] Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation
    Khouri, Issa F.
    Rima, Saliba M.
    Turturro, Francesco
    Korbling, Martin
    Ledesma, Celina
    Rondon, Gabriela
    Alousi, Amin M.
    Anderlini, Paolo
    Bashir, Qaiser
    Ciurea, Stefan O.
    Hosing, Chitra M.
    Popat, Uday R.
    Charafeddine, Yasmeen
    Oki, Yasuhiro
    Fayad, Luis E.
    Champlin, Richard E.
    BLOOD, 2012, 120 (21)
  • [38] Allogeneic hematopoietic stem cell transplantation (HSCT) with a reduced-intensity regimen (RIST) for non-Hodgkin lymphoma (NHL): a retrospective survey of 112 adults patients in Japan.
    Kusumi, E
    Tanimoto, TE
    Kami, M
    Hamaki, T
    Kim, S
    Mori, T
    Etoh, T
    Tamaki, T
    Taniguchi, S
    Takaue, Y
    BLOOD, 2003, 102 (11) : 729A - 729A
  • [39] Phase I study of myeloablative conditioning regimen of full-dose busulfan, melphalan, and fludarabine for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed aggressive lymphoma
    Koji, I.
    Hisashi, Y.
    Go, Y.
    Daisuke, K.
    Kosei, K.
    Mitsuhiro, Y.
    Aya, N.
    Kazuya, I.
    Shinsuke, T.
    Yuki, A-M
    Naoyuki, U.
    Akiko, Y.
    Shigeyoshi, M.
    Shuichi, T.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S451 - S451
  • [40] Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis
    Urbano-Ispizua, Alvaro
    Pavletic, Steven Z.
    Flowers, Mary E. D.
    Zhang, Mei-jie
    Carreras, Jeanette
    Smith, Sonali M.
    Maloney, David G.
    Montoto, Silvia
    Cutler, Corey S.
    Spellman, Stephen R.
    Arora, Mukta
    Saber, Wael
    BLOOD, 2013, 122 (21)
12345